Fixed-dose triple-combination treatments in the management of hypertension

Managed Care

Volumn 22, Issue 12, 2013, Pages 45-55

  Ram, C Venkata S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cost savings; Drug combinations; Hypertension; Medication adherence; Treatment outcome

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGED; ARTICLE; CLINICAL PRACTICE; COST CONTROL; DOSE RESPONSE; DRUG COMBINATION; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; METHODOLOGY; UNITED STATES;

AGED; ANTIHYPERTENSIVE AGENTS; COST SAVINGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES;

EID: 84893955163     PISSN: 10623388     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (71)

1. Angeli F, Reboldi G, Mazzotta G, et al. Fixeddose combination therapy in hypertension: cons. High Blood Press Cardiovasc Prev. 2012;19:51-54.
2. Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes. Diabetes Care. 2004;27 Suppl 1:S65-S67.
3. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/ AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2011;57:2037-2114.
4. Bailey JE, Wan JY, Tang J, et al. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med. 2010;25:495-503.
5. Black HR. Triple fixed-dose combination therapy. Back to the past. Hypertension. 2009;54:19-22.
6. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239-245.
7. Brixner DI, Jackson KC, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in freeand fixed-dose combinations. Curr Med Res Opin. 2008;24:2597-2607.
8. Calhoun DA, Lacourciere Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide. A randomized clinical trial. Hypertension. 2009a;54:32-39.
9. Calhoun DA, Crikelair NA, Yen J, et al. Amlodipine/ valsartan/hydrochlorothiazide triple combination therapy in moderate/ severe hypertension: Secondary analyses evaluating efficacy and safety. Adv Ther. 2009b;26:1012-1023.
10. Cherry SB, Benner JS, Hussein MA, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health. 2009;12:489-497.
11. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
12. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebocontrolled, 8-week factorial efficacy and safety study. Clin Ther. 2008a;30:587- 604.
13. Chrysant SG, Melino M, Karki S, et al. Onset of antihypertensive effect in patients with mild to severe hypertension treated with a combination of amlodipine besylate and olmesartan medoxomil compared with component monotherapy and placebo [abstract]. J Clin Hypertens. 2008b;10:A16.
14. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich). 2009;11:475-482.
15. Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension. 2011;58:566-572.
16. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
17. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9:2-6.
18. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8:45-50.
19. Domenech M, Coca A. Role of triple fixed combination valsartan, amlodipine and hydrochlorothiazide in controlling blood pressure. Patient Prefer Adherence. 2010;4:105-113.
20. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48:418-425.
21. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043-2050.
22. Elijovich F, Laffer C. A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis. 2009;3:231-240.
23. Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam Clin Pharmacol. 2010;24:3-8.
24. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53:646-653.
25. Ferdinand KC, Weitzman R, Israel M, et al. Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. J Am Soc Hypertens. 2011;5:102-113.
26. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220-224.
27. Fung V, Huang J, Brand R, et al. Hypertension treatment in a Medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29:972- 984.
28. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2013 update - a report from the American Heart Association. Circulation. 2013;127:143-152.
29. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010a;12:869-878.
30. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010b;4:42-50.
31. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixeddose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407.
32. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 Suppl 2:1-53.
33. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944.
34. Ho PM, Magid DJ, Shetterly SM, et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med. 2008;168:271-276.
35. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
36. Kettani FZ, Dragomir A, Cote R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40:213-220.
37. Lacourciere Y, Crikelair N, Glazer RD, et al. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011;25:615-622.
38. Lacourciere Y, Taddei S, Konis G, et al. Clinic and ambulatory blood pressure-lowering effect of aliskiren/ amlodipine/hydrochlorothiazide combination in patients with moderateto-severe hypertension: a randomized active-controlled trial. J Hypertens. 2012;30:2047-2055.
39. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: metaanalysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
40. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
41. Lu GC, Cheng JW, Zhu KM, et al. A systematic review of angiotensin receptor blockers in preventing stroke. Stroke. 2009;40:3876-3878.
42. Lv Y, Zou Z, Chen GM, et al. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Press Monit. 2010;15:195- 204.
43. National Kidney Foundation (NKF). KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 suppl 2):S12-S154.
44. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955- 1964.
45. Neutel JM, Smith DH, Weber MA. Low Dose Combination Therapy vs. High Dose Monotherapy in the Management of Hypertension. J Clin Hypertens (Greenwich). 1999;1:79-86.
46. Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35:539-543.
47. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108:684-690.
48. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252-1269.
49. Panjabi S, Lacey M, Bancroft T, et al. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens. 2013;7:46-60.
50. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
51. Perreault S, Dragomir A, White M, et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266:207-218.
52. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother. 2005;39:1401-1408.
53. Pittman DG, Tao Z, Chen W, et al. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16:568- 576.
54. Priest JL, Cantrell CR, Fincham J, et al. Quality of care associated with common chronic diseases in a 9-state Medicaid population utilizing claims data: an evaluation of medication and health care use and costs. Popul Health Manag. 2011;14:1-12.
55. Rabi DM, Daskalopoulou SS, Padwal RS, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2011;27:415-433.
56. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761- 2788.
57. Sharp SI, Aarsland D, Day S, et al. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry. 2011;26:661-669.
58. Sherrill B, Halpern M, Khan S, et al. Singlepill vs free-equivalent combination therapies for hypertension: a metaanalysis of health care costs and adherence. J Clin Hypertens. 2011;13:898- 909.
59. Staessen JA, Thijs L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22:847-857.
60. van Wijk BL, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23:2101-2107.
61. Verdecchia P, Gentile G, Angeli F, et al. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens. 2010;28:1356-1365.
62. Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007;3:999-1005.
63. Veterans Administration Cooperative Study Group on Antihypertensive Agents (VACSG). Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
64. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290-300.
65. Weir MR, Hsueh WA, Nesbitt SD, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ? hydrochlorothiazide. J Clin Hypertens (Greenwich). 2011;13:404-412.
66. Weir MR, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 2007;20:807-815.
67. World Health Organization (WHO). The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Available at: http://www.who.int/whr/2002/ en/whr02_en.pdf Accessed November 21, 2013.
68. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57:e215-e367.
69. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26:2065-2076.
70. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12:243-249.
71. Zeng F, Patel BV, Andrews L, et al. Adherence and persistence of single-pill ARB/ CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin. 2010;26:2877-2887.